Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Retained Earnings: 2016-2024

Historic Retained Earnings for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to -$806.2 million.

  • UroGen Pharma's Retained Earnings fell 21.42% to -$933.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$933.4 million, marking a year-over-year decrease of 21.42%. This contributed to the annual value of -$806.2 million for FY2024, which is 18.68% down from last year.
  • UroGen Pharma's Retained Earnings amounted to -$806.2 million in FY2024, which was down 18.68% from -$679.3 million recorded in FY2023.
  • Over the past 5 years, UroGen Pharma's Retained Earnings peaked at -$356.5 million during FY2020, and registered a low of -$806.2 million during FY2024.
  • Over the past 3 years, UroGen Pharma's median Retained Earnings value was -$679.3 million (recorded in 2023), while the average stood at -$687.6 million.
  • Data for UroGen Pharma's Retained Earnings shows a maximum YoY slumped of 56.35% (in 2020) over the last 5 years.
  • Over the past 5 years, UroGen Pharma's Retained Earnings (Yearly) stood at -$356.5 million in 2020, then crashed by 31.09% to -$467.3 million in 2021, then declined by 23.49% to -$577.1 million in 2022, then declined by 17.72% to -$679.3 million in 2023, then declined by 18.68% to -$806.2 million in 2024.